Recombinant vWF Type 2A Mutants R834Q and R834W Show a Defect in Mediating Platelet Adhesion to Collagen, Independent of Enhanced Sensitivity to a Plasma Protease

Summary

Type 2A von Willebrand Disease (vWD) is characterized by the absence of high molecular weight von Willebrand factor (vWF) multimers in plasma which is caused by enhanced extracellular proteolysis or defective intracellular transport. We identified in vWD type 2A patients two mutations in the A2 domain at position 834 in which arginine (R) was substituted for glutamine (R834Q) or tryptophan (R834W). We reproduced these mutations in vWF cDNA and expressed the recombinant proteins in furin cDNA containing baby hamster kidney (fur-BHK) cells. The subunit composition and the multimeric structure of both mutants was similar to wild-type (WT) vWF. Characterization of mutant R834Q by ristocetin or botrocetin induced platelet binding, and by binding to heparin showed no abnormality. R834W had normal botrocetin induced platelet binding, but ristocetin induced platelet binding and binding to heparin were decreased. Under static conditions R834Q and R834W, at 10 μg/ml, bound equally well to collagen type III as WT-vWF. At high shear rate conditions both mutants supported platelet adhesion normally when coated to a glass surface or preincubated on collagen. When R834Q or R834W was added to the perfusate, adhesion to collagen type III was 50% of the WT-vWF value, which was not due to a decreased collagen binding under flow. A divalent cation dependent protease, purified from plasma, degraded the 2A mutants rapidly while WT-vWF was not affected. In conclusion, the mutations present in the A2 domain of vWF result in an enhanced proteolytic sensitivity to a divalent ion-dependent protease. When present in the perfusate, R834Q and R834W show a decrease in platelet adhesion to collagen type III under flow conditions, which is not caused by decreased binding of the mutant vWF to collagen or enhanced proteolysis.

• References

• 1 Ruggeri ZM, Ware J. Von Willebrand factor. FASEB J 1993; 7: 308-16.
• 2 Sadler JE, Matsushita T, Dong Z, Tuley EA, Westfield LA. Molecular mechanism and classification of von Willebrand disease. Thromb Haemost 1995; 74: 161-6.
• 3 Ginsburg D, Sadler JE. Von Willebrand disease: A database of point mutations, insertions, and deletions. Thromb Haemost 1993; 69: 177-84.
• 4 Gralnick HR, Williams SB, McKeown LP, Maisonneuve P, Jenneau C, Sultan Y, Rick ME. In vitro correction of the abnormal multimeric structure of von Willebrand factor in type IIa von Willebrand’s disease. Proc Natl Acad Sci USA 1985; 82: 5968-72.
• 5 Battle J, Lopez Fernandez MF, Campos M, Justica B, Berges C, Navarro JL, Diaz Cremades JM, Kasper CK, Dent JA, Ruggeri ZM. et al The heterogeneity of type IIA von Willebrand’s disease: studies with protease inhibitors. Blood 1986; 68: 1207-12.
• 6 Dent JA, Berkowitz SD, Ware J, Kasper CK, Ruggeri ZM. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proceedings of the National Academy of Sciences of the United States of America 1990; 87: 6306-10.
• 7 Lyons SE, Bruck ME, Bowie EjW, Ginsburg D. Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations. J Biol Chem 1992; 267: 4424-30.
• 8 Lankhof H, Damas C, Schiphorst ME, Ijsseldijk MJW, Bracke M, Furlan M, Tsai HM, De Groot PG, Sixma JJ, Vink T. Von Willebrand factor without the A2 domain is resistant to proteolysis. Thromb Haemost 1997; 77: 1008-13.
• 9 Lankhof H, Wu Y-P, Vink T, Schiphorst ME, Zerwes H-G, De Groot PG, Sixma JJ. Role of the glycoprotein Ib-binding A1 repeat and the RGD sequence in platelet adhesion to human recombinant von Willebrand factor. Blood 1995; 86: 1035-42.
• 10 Hilbert L, Gaucher C, De Romeuf C, Horellou MH, Vink T, Mazurier C. Leu 697→Val mutation in mature von Willebrand factor is responsible for type IIB von Willebrand disease. Blood 1994; 83: 1542-50.
• 11 Higuchi R, Innis MA, Gelfand DH, Shinsky JJ, White TJ. editors PCR protocols-A guide to methods and applications. Academic Press inc.; 1990. Recombinant PCR
• 12 Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain termination inhibitors. Proc Natl Acad Sci USA 1977; 74: 5463-7.
• 13 Lankhof H, Van Hoeij M, Schiphorst ME, Bracke M, Wu YP, Ijsseldijk MJ, Vink T, De Groot PG, Sixma JJ. A3 domain is essential for interaction of von Willebrand factor with collagen type III. Thromb Haemost 1996; 75: 950-8.
• 14 Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87: 4223-34.
• 15 Sakariassen KS, Bolhuis PA, Sixma JJ. Human blood platelet adhesion to artery subendothelium is mediated by factor VIII von Willebrand factor bound to the subendothelium. Nature 1979; 279: 636-8.
• 16 Sakariassen KS, Aarts PAMM, De Groot PG, Houdijk WPM, Sixma JJ. A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix, and purified components. The Journal of Laboratory and Clinical Medicine 1983; 102: 522-35.
• 17 Van Zanten GH, Saelman EUM, Schut-Hese KM, Wu YP, Slootweg PJ, Nieuwenhuis HK, De Groot PG, Sixma JJ. Platelet adhesion to collagen type IV under flow conditions. Blood 1996; 88: 3862-71.
• 18 Turitto VT, Weiss HJ, Zimmerman TS, Sussman I I. Factor VIII/von Willebrand factor in subendothelium mediates platelet adhesion. Blood 1985; 65: 823-31.
• 19 Stel HV, Sakariassen KS, De Groot PG, van Mourik JA, Sixma JJ. Von Willebrand factor in the vessel wall mediates platelet adherence. Blood 1985; 65: 85-90.
• 20 Baruch D, Denis C, Marteaux C, Schoevaert D, Coulombel L, Meyer D. Role of von Willebrand factor associated to extracellular matrices in platelet adhesion. Blood 1991; 77: 519-27.
• 21 Wagner DD, Urban-Pickering M, Marder V. Von Willebrand factor binds to extracellular matrices independently of collagen. Proc Natl Acad Sci USA 1984; 81: 471-5.
• 22 De Groot PG, Ottenhof-Rovers M, van Mourik JA, Sixma JJ. Evidence that the primary binding site of von Willebrand factor that mediates platelet adhesion on subendothelium is not collagen. J Clin Invest 1988; 82: 65-73.
• 23 Houdijk WPM, Sakariassen KS, Nievelstein PFEM, Sixma JJ. Role of Factor VIII-von Willebrand factor and Fibronectin in the interaction of platelets in flowing blood with monomeric and fibrillar human collagen types I and III. J Clin Invest 1985; 75: 1-10.
• 24 Ginsburg D, Konkle BA, Gill JC, Montgomery RR, Bockenstedt PL, Johnson TA, Yang AY. Molecular basis of human von Willebrand disease: Analysis of platelet von Willebrand factor mRNA. Proceedings of the National Academy of Sciences of the United States of America 1989; 86: 3723-7.
• 25 Dent JA, Galbusera M, Ruggeri ZM. Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit. Journal of Clinical Investigation 1991; 88: 774-82.
• 26 Kunicki TJ, Montgomery RR, Schullek J. Cleavage of human von Willebrand factor by platelet calcium-activated protease. Blood 1985; 65: 352-6.
• 27 Tsai HM, Sussman I I, Ginsburg D, Lankhof H, Sixma JJ, Nagel RL. Proteolytic cleavage of recombinant type 2A von Willebrand factor mutants R834W and R834Q: Inhibition by doxycycline and by monoclonal antibody VP-1. Blood 1997; 89: 1954-62.
• 28 Levene RB, Booyse FM, Chediak J, Zimmerman TS, Livingstone DM, Lynch DC. Expression of abnormal von Willebrand factor by endothelial cells from a patient with type IIA von Willebrand disease. Proc Natl Acad Sci USA 1987; 84: 6550-4.
• 29 Ginsburg D, Bowie EJ. Molecular genetics of von Willebrand disease. Blood 1992; 79: 2507-19.
• 30 Wu YP, Van Breugel I HHF, Lankhof H, Wise RJ, Handin I R, De Groot PG, Sixma JJ. Platelet adhesion to multimeric and dimeric von Willebrand factor and to collagen type III preincubated with von Willebrand factor. Arterioscler Thromb Vasc Biol 1996; 16: 611-20.